PORT

GPC3/CD3 bispecific antibody for all solid tumors with GPC3 expression.

Status:

Open

Trial Type:

Early Phase Trials for Multiple Cancer Types, Liver and Bile Duct Cancer

Contact:

Khaldoun Almhanna, MD

kalmhanna@brownhealth.org